Eptifibatide

Is the active ingredient.

Prevention of adverse cardiovascular events in patients undergoing percutaneous coronary intervention (PCI).

Treatment of unstable angina or nonST-segment elevation myocardial infarction (NSTEMI).

Fleta Iv 100ml (Eptifibatide) is a glycoprotein IIb/IIIa receptor antagonist. It prevents platelets from aggregating (clumping together), thereby inhibiting thrombus (blood clot) formation. This reduces the risk of heart attack and stroke.

Store at controlled room temperature (20-25°C). Protect from light and moisture. Discard any unused portion after the expiration date.

Dosage and administration are determined by a physician based on individual patient needs and condition. It is typically administered intravenously.

Always follow your doctor's or healthcare provider's instructions precisely.

Thrombocytopenia (low platelet count).

Nausea.

Headache.

Hypotension (low blood pressure).

Allergic reactions (rash, itching, swelling).

Alcohol Consumption

Alcohol consumption should be discussed with your doctor, as it can increase bleeding risk.



While Driving or operating Machinery

May cause dizziness or drowsiness; avoid driving or operating machinery if affected.



Pregnant & Breastfeeding Women

Use during pregnancy or breastfeeding is generally not recommended unless the benefits outweigh the risks. Consult your doctor.



Children

Not indicated for use in children.



Kidney

Dose adjustment may be necessary in patients with impaired kidney function.



Liver

The effect of liver impairment on eptifibatide is not fully established; consult your doctor.

Consult your physician or pharmacist for complete prescribing information.

Refer to the official drug monograph provided by the FDA or equivalent regulatory authority in your country.